Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

2019 ◽  
Vol 20 (5) ◽  
Author(s):  
Nieves Martinez Chanza ◽  
Abhishek Tripathi ◽  
Lauren C. Harshman
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapy Options

Adjuvant Therapy in Renal Cell Carcinoma: Current Stance and Future Directions

Kidney Cancer ◽  
2021 ◽  
pp. 1-12
Author(s):  
Austin G. Kazarian ◽  
Neal S. Chawla ◽  
Ramya Muddasani ◽  
Sumanta K. Pal
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Checkpoint Inhibitors ◽  
Unmet Need ◽  
Disease Free Survival ◽  
Adjuvant Setting ◽  
Metastatic Setting

In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite advances in the metastatic setting, effective therapies in the adjuvant setting are a largely unmet need. Currently, sunitinib (Sutent, Pfizer) is the only therapy for the adjuvant treatment of RCC included in the National Comprehensive Cancer Network guidelines, which was approved by the FDA based on the improvement in disease-free survival (DFS) seen in the S-TRAC trial. However, improvement in DFS has not translated into an overall survival (OS) benefit for patients at high-risk of relapse post-nephrectomy, illustrating the need for more effective therapies. This manuscript will highlight attributes of both historical and current drug trials and their implications on the landscape of adjuvant therapy. Additionally, we will outline strategies for selecting patients in whom treatment would be most beneficial, as optimal patient selection is a crucial step towards improving outcomes in the adjuvant setting. This is especially critical, given the financial cost and pharmacological toxicity of therapeutic agents. Furthermore, we will review the design of clinical trials including the value of utilizing OS as an endpoint over DFS. Finally, we will discuss how the incorporation of genomic data into predictive models, the use of more sensitive imaging modalities for more accurate staging, and more extensive surgical intervention involving lymph node dissection, may impact outcomes.

Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives

2021 ◽  
pp. 102207
Author(s):  
Mathieu Larroquette ◽  
Florent Peyraud ◽  
Charlotte Domblides ◽  
Félix Lefort ◽  
Jean-Christophe Bernhard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Future Perspectives

scholarly journals Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy

Medicine ◽  
2019 ◽  
Vol 98 (5) ◽  
pp. e14237 ◽  
Author(s):  
Di Wei ◽  
Guojun Wu ◽  
Yu Zheng ◽  
Fubao Chen ◽  
Jingyi Lu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Chinese Patients

scholarly journals Clinical Efficacy of Sunitinib as Post-Operative Adjuvant Therapy in Patients with High-Risk Renal Cell Carcinoma

2012 ◽  
Vol 23 ◽  
pp. ix281
Author(s):  
X. Zhang ◽  
J.Y. Yuan ◽  
L. Wang ◽  
L. Chen ◽  
J. Pan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Clinical Efficacy ◽  
Renal Cell

Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?

2016 ◽  
Vol 34 (5) ◽  
pp. 221-224 ◽  
Author(s):  
Reza Mehrazin ◽  
Che-Kai Tsao ◽  
John Sfakianos ◽  
Matthew D. Galsky
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Systemic Adjuvant Therapy

COMBINATION IMMUNOCHEMOTHERAPY AS AN ADJUVANT THERAPY FOR STAGE T3 RENAL CELL CARCINOMA

2006 ◽  
Vol 5 (2) ◽  
pp. 258
Author(s):  
S.K. Hong ◽  
I.H. Chang ◽  
M.C. Gil ◽  
Y.J. Kim ◽  
S.B. Lee ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell

Adjuvant therapy for advanced renal cell carcinoma

2018 ◽  
Vol 18 (7) ◽  
pp. 663-671 ◽  
Author(s):  
Matthew A. Meissner ◽  
Barrett Z. McCormick ◽  
Jose A. Karam ◽  
Christopher G. Wood
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma

Adjuvant therapy of renal cell carcinoma (RCC) with a pure cell-lysate autologous tumorvaccine (aTm)

1997 ◽  
Vol 33 ◽  
pp. S89
Author(s):  
C. Ulbrich ◽  
R. Repmann ◽  
A.J.W. Goldschmidt ◽  
S.W. Hockertz
Keyword(s):  
Renal Cell Carcinoma ◽  
Adjuvant Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cell Lysate ◽  
Pure Cell
Sign in / Sign up

Export Citation Format

Share Document